Because the researchers found that CTLA4Ig was
effective in suppressing hepatitis in this study, they
suggest that CTLA4Ig should be among the
therapeutic options investigated further as a potential therapy for patients with severe acute hepatitis B. To this end, this animal model is useful for virological and immunological analysis of HBV infection.